SEARCH

SEARCH BY CITATION

References

  • 1
    Mor G, Cardenas I: The immune system in pregnancy: a unique complexity. Am J Reprod Immunol 2010; 63:425433.
  • 2
    Redman CWG, Sargent IL: Immunology of pre-eclampsia. Am J Reprod Immunol 2010; 63:534543.
  • 3
    Dekel N, Gnainsky Y, Granot I, Mor G: Inflammation and implantation. Am J Reprod Immunol 2010; 63:1721.
  • 4
    Moser G, Gauster M, Orendi K, Glasner A, Theuerkauf R, Huppertz B: Endoglandular trophoblast, an alternative route of trophoblast invasion? Analysis with novel confrontation co-culture models. Hum Reprod 2010; 25:11271136.
  • 5
    Fitzgerald JS, Germeyer A, Huppertz B, Jeschke U, Knöfler M, Moser G, Scholz C, Sonderegger S, Toth B, Markert UR: Governing the invasive trophoblast: current aspects on intra- and extracellular regulation. Am J Reprod Immunol 2010; 63:492505.
  • 6
    Burton GJ, Jauniaux E, Charnock-Jones DS: Human early placental development: potential roles of the endometrial glands. Placenta 2007; 28(Suppl A):S64S69.
  • 7
    Daher S, de Arruda Geraldes Denardi K, Blotta MH, Mamoni RL, Reck AP, Camano L, Mattar R: Cytokines in recurrent pregnancy loss. J Reprod Immunol 2004; 62:151157.
  • 8
    Clark DA, Yu G, Arck PC, Levy GA, Gorczynski RM: MD-1 is a critical part of the mechanism causing Th1-cytokine-triggered murine fetal loss syndrome. Am J Reprod Immunol 2003; 49:297307.
  • 9
    Kwak-Kim J, Yang KM, Gilman-Sachs A: Recurrent pregnancy loss: a disease of inflammation and coagulation. J Obstet Gynaecol Res 2009; 35:609622.
  • 10
    Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE: Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203:21652175.
  • 11
    Gomez-Lopez N, Guilbert LJ, Olson DM: Invasion of the leukocytes into the fetal-maternal interface during pregnancy. J Leukoc Biol 2010; 88:625633.
  • 12
    Ashkar AA, Di Santo JP, Croy BA: Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy. J Exp Med 2000; 192:259270.
  • 13
    van den Heuvel MJ, Xie X, Tayade C, Peralta C, Fang Y, Leonard S, Paffaro Jr VA, Sheikhi AK, Murrant C, Croy BA: A review of trafficking and activation of uterine natural killer cells. Am J Reprod Immunol 2005; 54:322331.
  • 14
    Harris LK: IFPA Gabor Than Award lecture: transformation of the spiral arteries in human pregnancy: key events in the remodelling timeline. Placenta 2011; 32(Suppl 2):S154S158.
  • 15
    Moffett-King A: Natural killer cells and pregnancy. Nat Rev Immunol 2002; 2:656663.
  • 16
    Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I, Gazit R, Yutkin V, Benharroch D, Porgador A, Keshet E, Yagel S, Mandelboim O: Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006; 12:10651074.
  • 17
    Mosser DM, Edwards JP: Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8:958969.
  • 18
    Strazewski Chavez SL, Abrahams VM, Mor G: The role of apoptosis in the regulation of trophoblast survival and differentiation during pregnancy. Endocr Rev 2005; 26:877897.
  • 19
    Fest S, Aldo PB, Abrahams VM, Visintin I, Alvero A, Chen R, Chavez SL, Romero R, Mor G: Trophoblast-macrophage interactions: a regulatory network for the protection of pregnancy. Am J Reprod Immunol 2007; 57:5566.
  • 20
    Abrahams VM, Kim YM, Straszewski SL, Romero R, Mor G: Macrophages and apoptotic cell clearance during pregnancy. Am J Reprod Immunol 2004; 51:275282.
  • 21
    Nagamatsu T, Schust DJ: The contribution of macrophages to normal and pathological pregnancies. Am J Reprod Immunol 2010; 63:460471.
  • 22
    Aluvihare VR, Kallikourdis M, Betz AG: Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004; 5:266271.
  • 23
    Terness P, Kallikourdis M, Betz AG, Rabinovich GA, Saito S, Clark DA: Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cells. Am J Reprod Immunol 2007; 58:238254.
  • 24
    Leber A, Teles A, Zenclussen AC: Regulatory T cells and their role in pregnancy. Am J Reprod Immunol 2010; 63:445459.
  • 25
    Zenclussen AC, Gerlof K, Zenclussen ML, Sollwedel A, Bertoja AZ, Ritter T, Kotsch K, Leber J, Volk HD: Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. Am J Pathol 2005; 166:811822.
  • 26
    Ramhorst R, Fraccaroli L, Aldo P, Alvero AB, Cardenas I, Perez Leirós C, Mor G: Modulation and recruitment of inducible regulatory T cells by first trimester trophoblast cells. Am J Reprod Immunol 2012; 67:1727.
  • 27
    Saito S, Nakashima A, Shima T, Ito M: Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol 2010; 63:601610.
  • 28
    Schumacher A, Wafula PO, Teles A, El-Mousleh T, Linzke N, Zenclussen ML, Langwisch S, Heinze K, Wollenberg I, Casalis PA, Volk HD, Fest S, Zenclussen AC: Blockage of heme oxygenase-1 abrogates the protective effect of regulatory T cells on murine pregnancy and promotes the maturation of dendritic cells. PLoS ONE 2012; 7:e42301.
  • 29
    Munoz-Suano A, Hamilton AB, Betz AG: Gimme shelter: the immune system during pregnancy. Immunol Rev 2011; 241:2038.
  • 30
    Warning JC, McCracken SA, Morris JM: A balancing act: mechanisms by which the fetus avoids rejection by the maternal immune system. Reproduction 2011; 141:715724.
  • 31
    Rossi D, Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18:217242.
  • 32
    Bromley SK, Mempel TR, Luster AD: Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008; 9:970980.
  • 33
    Fraccaroli L, Alfieri J, Pérez Leiros C, Ramhorst R: Immunomodulatory effects of chemokines during the early implantation window. Front Biosc 2009; 1:288298.
  • 34
    Lutther AJ, Cyster AC: Chemokines as regulators of T cell differentiation. Nat Med 2001; 2:102107.
  • 35
    Moser B, Loetscher P: Lymphocyte traffic control by chemokines. Nat Med 2001; 2:123128.
  • 36
    Sohy D, Yano H, de Nadai P, Urizar E, Guillabert A, Javitch JA, Parmentier M, Springael JY: Hetero-oligomerization of CCR2,CCR5, and CXCR4 and the protean effects of “selective” antagonists. J Biol Chem 2009; 284:3127031279.
  • 37
    Raman D, Sobolik-Delmaire T, Richmond A: Chemokines in health and disease. Exp Cell Res 2011; 317:575589.
  • 38
    Neel NF, Barzik M, Raman D, Sobolik-Delmaire T, Sai J, Ham AJ, Mernaugh RL, Gertler FB, Richmond A: VASP is a CXCR2-interacting protein that regulates CXCR2-mediated polarization and chemotaxis. J Cell Sci 2009; 122:18821894.
  • 39
    Raman D, Neel NF, Sai J, Mernaugh RL, Ham AJ, Richmond AJ: Characterization of chemokine receptor CXCR2 interacting proteins using a proteomics approach to define the CXCR2 “chemosynapse”. Methods Enzymol 2009; 460:315330.
  • 40
    Raman D, Sai J, Neel NF, Chew CS, Richmond A: LIM and SH3 protein-1 modulates CXCR2- mediated cell migration. PLoS ONE 2010; 5:e10050.
  • 41
    Kallikourdis M, Andersen KG, Welch KA, Betz AG: Alloantigen-enhanced accumulation of CCR5+ effector regulatory T cells in the gravid uterus. PNAS 2007; 104:594599.
  • 42
    Mold JE, Michaëlsson J, Burt TD, Muench MO, Beckerman PK, Busch MP, Lee T, Nixon DF, McCune JM: Maternal alloantigens promote the development of tolerogenic fetal regulatory t cells in utero. Science 2008; 322:15621565.
  • 43
    Mjösberg J, Svensson J, Johansson E, Hellström L, Casas R, Jenmalm MC, Boij R, Matthiesen L, Jönsson JI, Berg G, Ernerudh J: Systemic reduction of functionally suppressive CD4dimCD25highFoxp3+ Tregs in human second trimester pregnancy is induced by progesterone and 17beta-estradiol. J Immunol 2009; 183:759769.
  • 44
    Mjösberg J, Berg G, Jenmalm MC, Ernerudh J: FOXP3+ regulatory T cells and T helper 1, T helper 2, and T helper 17 cells in human early pregnancy decidua. Biol Reprod 2010; 82:698705.
  • 45
    Tilburgs T, Roelen DL, van der Mast BJ, de Groot-Swings GM, Kleijburg C, Scherjon SA, Claas FH: Evidence for a selective migration of fetus-specific CD4+CD25bright regulatory T cells from the peripheral blood to the decidua in human pregnancy. J Immunol 2008; 180:57375745.
  • 46
    Tilburgs T, Schonkeren D, Eikmans M, Nagtzaam NM, Datema G, Swings GM, Prins F, van Lith JM, van der Mast BJ, Roelen DL, Scherjon SA, Claas FH: Human decidual tissue contains differentiated CD8+ effector-memory T cells with unique properties. J Immunol 2010; 185:44704477.
  • 47
    Graham CH, Hawley TS, Hawley RG, MacDougall JR, Kerbel RS, Khoo N, Lala PK: Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp Cell Res 1993; 206:204211.
  • 48
    Straszewski-Chavez SL, Abrahams VM, Alvero AB, Aldo PB, Ma Y, Guller S, Romero R, Mor G: The isolation and characterization of a novel telomerase immortalized first trimester trophoblast cell line, Swan 71. Placenta 2009; 30:939948.
  • 49
    Nancy P, Tagliani E, Tay CS, Asp P, Levy DE, Erlebacher A: Chemokine gene silencing in decidual stromal cells limits T cell access to the maternal-fetal interface. Science 2012; 336:13171321.
  • 50
    Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1αand MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270:18111815.
  • 51
    Hornung D, Klingel K, Dohrn K, Kandolf R, Wallwiener D, Tayler RN: Regulated on activation, normal T-cell expressed and –secreted mRNA expression in normal endometrium and endometriotic implants: assessment of autocrine/paracrine regulation by in situ hybridization. Am J Pathol 2001; 158:19491954.
  • 52
    Faunce D, Stein-Streilein J: NKT Cell-derived RANTES recruits APCs and CD8+ T cells to the spleen during the generation of regulatory T cells in tolerance. J Immunol 2002; 169:3138.
  • 53
    Nakamura T, Sonoda K, Faunce D, Gumperz J, Yamamura T, Miyake S, Stein-Streilein T: CD4+ NKT cells, but not conventional CD4+ T cells are required to generate efferent CD8+ T regulatory cells following antigen inoculation in an immune-privileged site. J Immunol 2003; 171:12661271.
  • 54
    Rabinovich GA, Ramhorst RE, Rubinstein N, Corigliano A, Daroqui MC, Kier-Joffé EB, Fainboim L: Induction of allogenic T-cell hyporesponsiveness by galectin-1-mediated apoptotic and non-apoptotic mechanisms. Cell Death Differ 2002; 9:661670.
  • 55
    Ramhorst R, Patel R, Corigliano A, Etchepareborda JJ, Fainboim L, Schust D: Induction of maternal tolerance to fetal alloantigens by RANTES production. Am J Reprod Immunol 2006; 56:302311.
  • 56
    Paria B, Reese J, Das S, Dey S: Deciphering the cross talk of implantation: advances and challenges. Science 2002; 296:21852188.
  • 57
    Fraccaroli L, Alfieri J, Larocca L, Calafat M, Mor G, Pérez Leiros C, Ramhorst R: A potential tolerogenic immune mechanism in a trophoblast cell line through the activation of chemokine-induced T cell death and regulatory T cell modulation. Hum Reprod 2009; 24:166175.
  • 58
    Ramhorst R, Gutiérrez G, Corigliano A, Junovich G, Fainboim L: Implication of RANTES in the modulation of alloimmune response by progesterone during pregnancy. Am J Reprod Immunol 2007; 57:147152.
  • 59
    Kim MJ, Romero R, Kim CJ, Tarca AL, Chhauy S, LaJeunesse C, Lee DC, Draghici S, Gotsch F, Kusanovic JP, Hassan SS, Kim JS: Villitis of unknown etiology is associated with a distinct pattern of chemokine up-regulation in the feto-maternal and placental compartments: implications for conjoint maternal allograft rejection and maternal anti-fetal graft-versus-host disease. J Immunol 2009; 182:39193927.
  • 60
    Fraccaroli L, Grasso E, Hauk V, Cortelezzi M, Calo G, Pérez Leirós C, Ramhorst R: Defects in the vasoactive intestinal peptide (VIP)/VPAC system during early stages of the placental-maternal leucocyte interaction impair the maternal tolerogenic response. Clin Exp Immunol 2012; 170:310320.
  • 61
    Said SI: The discovery of VIP: initially looked for in the lung, isolated from intestine, and identified as a neuropeptide. Peptides 2007; 28:16201621.
  • 62
    Couvineau A, Laburthe M: VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol 2012; 166:4250.
  • 63
    Onoue S, Misaka S, Yamada S: Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. Naunyn-Schmiedeberg's Arch Pharmacol 2008; 377:579590.
  • 64
    Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA, Said SI: Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 2012; 166:417.
  • 65
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. J Immunol 1999; 162:46854696.
  • 66
    Gressens P, Marret S, Hill JM, Brenneman DE, Gozes I, Fridkin M, Evrard P: Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J Clin Invest 1997; 100:390397.
  • 67
    Månsson B, Nilsson BO, Ekström J: Effects of repeated infusions of substance P and vasoactive intestinal peptide on the weights of salivary glands subjected to atrophying influences in rats. Br J Pharmacol 1990; 101:853858.
  • 68
    Ekström J, Mansson B, Tobin G: Vasoactive intestinal peptide evokes secretion of fluid and protein from rat salivary glands and the development of supersensitivity. Acta Physiol Scand 1983; 119:169175.
  • 69
    Jovanovic S, Grbovic L, Jovanovic A: Pregnancy does not alter the response of uterine arteries to vasoactive intestinal polypeptide. Mol Hum Reprod 2000; 6:361368.
  • 70
    Roca V, Larocca L, Calafat M, Aisemberg J, Meiss R, Franchi A, Perez Leiros C: Reduced nitric oxide synthase and cyclo-oxygenase activity in the uterus of non-obese diabetic mice. Reproduction 2006; 32:931938.
  • 71
    Lara-Marquez M, O'Dorisio M, O'Dorisio T, Shah M, Karacay B: Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J Immunol 2006; 166:25222530.
  • 72
    Martinez C, Delgado M, Abad C, Gomariz RP, Ganea D, Leceta J: Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol 1999; 93:126138.
  • 73
    Li JM, Southerland L, Hossain MS, Giver CR, Wang Y, Darlak K, Harris W, Waschek J, Waller EK: Absence of vasoactive intestinal peptide expression in hematopoietic cells enhances Th1 polarization and antiviral immunity in mice. J Immunol 2011; 187:10571065.
  • 74
    Lodde BM, Mineshiba F, Wang J, Cotrim P, Afione S, Tak PP, Baum BJ: Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 2006; 65:195200.
  • 75
    Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP: Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001; 7:563568.
  • 76
    Gonzalez-Rey E, Delgado M: Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 2007; 13:241251.
  • 77
    Yadav M, Goetzl EJ: Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity. Ann N Y Acad Sci 2008; 1144:8389.
  • 78
    Jimeno R, Gomariz RP, Gutiérrez-Cañas I, Martínez C, Juarranz Y, Leceta J: New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol Cell Biol 2010; 88:734745.
  • 79
    Rosignoli F, Torroba M, Juarranz Y, Gomez IA, Martinez C, Gomariz RP, Pérez Leirós C, Leceta J: VIP and tolerance induction in autoimmunity. Ann N Y Acad Sci 2006; 6:16.
  • 80
    Chorny A, Gonzalez-Rey E, Fernandez Martin A, Ganea D, Delgado M: Vasointestinal peptide induces regulatory dendritic cells that prevent acute graft-host disease while maintaining the graft-versus tumor response. Blood 2006; 107:37873794.
  • 81
    Toscano MG, Delgado M, Kong W, Martin F, Skarica M, Ganea D: Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol Ther 2010; 18:10351045.
  • 82
    Juarranz MG, Santiago B, Torroba M, Gutierrez-Cañas I, Palao G, Galindo M, Abad C, Martinez C, Leceta J, Pablos JL, Gomariz RP: Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology 2004; 43:416422.
  • 83
    Carrión M, Juarranz Y, Pérez-García S, Jimeno R, Pablos JL, Gomariz RP, Gutiérrez-Cañas I: RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: immune regulation by vasoactive intestinal peptide. Arthritis Rheum 2011; 63:16261636.
  • 84
    Jimeno R, Leceta J, Martínez C, Gutiérrez-Cañas I, Pérez-García S, Carrión M, Gomariz RP, Juarranz Y: Effect of VIP on the balance between cytokines and master regulators of activated helper T cells. Immunol Cell Biol 2012; 90:178186.
  • 85
    Pozo D, Anderson P, Gonzalez-Rey E: Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide. J Immunol 2009; 183:43464359.
  • 86
    Yadav M, Rosenbaum J, Goetzl EJ: Cutting edge: vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J Immunol 2008; 180:27722776.
  • 87
    Said SI, Hamidi SA, Gonzalez Bosc L: Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis? Eur Respir J 2010; 35:730734.
  • 88
    Leceta J, Martínez C, Delgado M, Garrido E, Gomariz RP: Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Adv Neuroimmunol 1996; 6:2936.
  • 89
    Voice JK, Grinninger C, Kong Y, Bangale Y, Paul S, Goetzl EJ: Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol 2003; 170:308314.
  • 90
    Hill JM, McCune SK, Alvero RJ, Glazner GW, Henins KA, Stanziale SF, Keimowitz JR, Brenneman DE: Maternal vasoactive intestinal peptide and the regulation of embryonic growth in the rodent. J Clin Invest 1996; 97:202208.
  • 91
    Spong CY, Lee SJ, McCune SK, Gibney G, Abebe DT, Brenneman DE, Hill JM: Regulation of postimplantation mouse embryonic growth by maternal vasoactive intestinal peptide. Ann N Y Acad Sci 1999; 897:101108.
  • 92
    Spong C, Lee S, Mcune S, Gibney G, Abebe D, Alvero R, Brenneman E, Hill G: Maternal regulation of embryonic growth: the role of vasoactive intestinal peptide. Endocrinology 1999; 140:917924.
  • 93
    Hill JM, Hauser JM, Sheppard LM, Abebe D, Spivak-Pohis I, Kushnir M, Deitch I, Gozes I: Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. J Mol Neurosci 2007; 31:183200.
  • 94
    Gressens P, Paindaveine B, Hill JM, Evrard P, Brenneman DE: Vasoactive intestinal peptide shortens both G1 and S phases of neural cell cycle in whole postimplantation cultured mouse embryos. Eur J Neurosci 1994; 10:17341742.
  • 95
    Tyrrell S, Landis SC: The appearance of NPY and VIP in sympathetic neuroblasts and subsequent alterations in their expression. J Neurosci 1994; 14:45294547.
  • 96
    Lim MA, Stack CM, Cuasay K, Stone MM, McFarlane HG, Waschek JA, Hill JM: Regardless of genotype, offspring of VIP-deficient female mice exhibit developmental delays and deficits in social behavior. Int J Dev Neurosci 2008; 26:423434.
  • 97
    Graf AH, Hütter W, Hacker GW, Steiner H, Anderson V, Staudach A, Dietze O: Localization and distribution of vasoactive neuropeptides in the human placenta. Placenta 1996; 17:413421.
  • 98
    Marzioni D, Fiore G, Giordano A, Nabissi M, Florio P, Verdenelli F, Petraglia F, Castellucci M: Placental expression of substance P and vasoactive intestinal peptide: evidence for a local effect on hormone release. J Clin Endocrinol Metab 2005; 90:23782383.
  • 99
    Deutsch PJ, Sun Y, Kroog GS: Vasoactive intestinal peptide increases intracellular cAMP and gonadotropin-alpha gene activity in JEG-3 syncytial trophoblasts. Constraints posed by desensitization. J Biol Chem 1990; 265:1027410281.
  • 100
    Ottesen B, Ulrichsen H, Fahrenkrug J, Larsen JJ, Wagner G, Schierup L, Søndergaard F: Vasoactive intestinal polypeptide and the female genital tract: relationship to reproductive phase and delivery. Am J Obstet Gynecol 1982; 143:414420.
  • 101
    Roca V, Calafat M, Larocca L, Ramhorst R, Farina M, Franchi AM, Pérez Leiros C: Potential immunomodulatory role of VIP in the implantation sites of prediabetic nonobese diabetic mice. Reproduction 2009; 138:733742.
  • 102
    Larocca L, Hauk V, Calafat M, Roca V, Fraccaroli L, Franchi A, Ramhorst R, Pérez Leiros C: Modulation of macrophage inflammatory profile in pregnant nonobese diabetic (NOD) mice. Mol Cell Endocrinol 2011; 333:112118.
  • 103
    Fraccaroli L, Alfieri J, Larocca L, Calafat M, Roca V, Lombardi E, Ramhorst R, Pérez Leirós C: VIP modulates the pro-inflammatory maternal response, inducing tolerance to trophoblast cells. Br J Pharmacol 2009; 156:116126.
  • 104
    Fraccaroli L, Grasso E, Zeitler E, Lombardi E, Gogorza S, Etchepareborda JJ, Nagle C, Cortelezzi M, Pérez Leirós C, Ramhorst R: Modulation of maternal LIF producers T cells by trophoblast and paternal antigens. Am J Reprod Immunol 2011; 65:133145.
  • 105
    Ilarregui JM, Croci DO, Bianco GA, Toscano MA, Salatino M, Vermeulen ME, Geffner JR, Rabinovich GA: Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 2009; 10:981991.
  • 106
    Ramhorst RE, Giribaldi L, Fraccaroli L, Toscano MA, Stupirski JC, Romero MD, Durand ES, Rubinstein N, Blaschitz A, Sedlmayr P, Genti-Raimondi S, Fainboim L, Rabinovich GA: Galectin-1 confers immune privilege to human trophoblast: implications in recurrent fetal loss. Glycobiology 2012; 22:13741386.
  • 107
    Blois SM, Ilarregui JM, Tometten M, Garcia M, Orsal AS, Cordo-Russo R, Toscano MA, Bianco GB, Kobelt P, Handjiski B, Tirado I, Markert UR, Klapp BF, Poirier F, Szekeres-Bartho J, Rabinovich GA, Arck PC: A pivotal role for galectin-1 in fetomaternal tolerance. Nat Med 2007; 13:14501457.
  • 108
    Rabinovich GA, Croci DO: Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012; 36:322335.
  • 109
    Than NG, Romero R, Kim CJ, McGowen MR, Papp Z, Wildman DE: Galectins: guardians of eutherian pregnancy at the maternal-fetal interface. Trends Endocrinol Metab 2012; 23:2331.
  • 110
    Than NG, Erez O, Wildman DE, Tarca AL, Edwin SS, Abbas A, Hotra J, Kusanovic JP, Gotsch F, Hassan SS, Espinoza J, Papp Z, Romero R: Severe preeclampsia is characterized by increased placental expression of galectin-1. J Matern Fetal Neonatal Med 2008; 21:429442.